U.S. Biosimilars Market Estimations (2025 - 2035)

U.S. Biosimilars Market Estimations (2025 - 2035)

The U.S. biosimilars market covers biosimilar and interchangeable biosimilar medicines licensed by the FDA under section 351(k) and sold in the United States, including monoclonal antibody, insulin, G-CSF and other protein biosimilars, for immunology, oncology and supportive care, bone health, ophthalmology, diabetes and other uses, under Medicare Part B, Part D and commercial coverage.

📄Report ID:2525 | 📊Format: Databook | 📅Published: 19 November 2026 | ⚡Delivery: Immediate